CCB International believes that Corning Jerry Pharmaceutical...

Moomoo AI Oct 20, 2023 16:57

CCB International believes that Corning Jerry Pharmaceuticals is becoming increasingly competitive in the field of NSCLC treatment, and that the reading of KN046-301 trial data that the company had previously postponed and the relevant data updates at ESMO 2023 did not increase the bank's confidence in its successful development of NSCLC treatment.

CBI: Maintains Corning Jerry Pharmaceutical-B (09966) “neutral” rating target price of HK$9

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

See Original

Report

2882 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4662Followers

0Following

10KVisitors